InforMedix has positioned itself for success in the projected billion dollar ePRO industry thanks to years of significant investment in extensive research. Founded in 1997 as an R&D company, the firm spent its initial years developing technology and prototype product for collecting patient information, improving patient/physician communication, and monitoring disease management. A direct outcome of this early jumpstart is the firm's pioneer patent position in the area of medication compliance monitoring and the correlation of dose-response data and its current portfolio of 29 issued or pending patents. InforMedix went public in 2003 for the purposes of gaining access to the public financial markets and commercializing its flagship product, the Med-eMonitor System. As the only public firm in the ePRO field, the company offers current and prospective clients the highest degree of disclosure and accountability, as well as the financial stability provided by public markets. Moreover, its Board of Directors and Advisory Board members bring keen insight from many of the world's largest pharmas. The firm has also reaped its share of technical recognition through awards and trials that have been published in peer reviewed medical journals.